european medicines agency glp-1 vision loss recommendation november 2025 Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 Researchers move closer to matching

For example, a dual synergistic nanoreactor incorporating dihydroquercetin and platinum nanocatalysts within mannose-modified OL-NP demonstrated robust neuroprotection by reducing neuronal injury and modulating microglial activation toward an anti-inflammatory M2 phenotype [299]

Establishing clear treatment goals and monitoring plans ensures safe, effective use of both medications and helps optimize your overall metabolic and hormonal health

doi:10.1172/jci.insight.141851 227

However, for patients who have already reached a healthy weight, microdosing may help maintain results while potentially providing ongoing metabolic benefits with fewer side effects